A Randomized Trial comparing 6 Â½ weeks radiotherapy treatment (66 Grey total radiation dose) combined with chemotherapy versus 5 weeks accelerated radiotherapy alone (67.5 Grey) in Stage III/IV (locally advanced ) Oropharyngeal cancers.

A Randomized trial comparing Accelerated Radiotherapy with Concomitant Boost schedule versus Concurrent Conventional Chemo-radiation in locally Advanced Oropharyngeal cancers.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/01/002369

Enrollment

100

Registered

2012-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CANCER

Interventions

Intervention1: radiotherapy, : radiation: 67.5 Gy/25 fractions/5weeks in Concomitant boost Arm. Control Intervention1: chemotherapy radiotherapy: 66Gy/33 fractions/6 1/2 weeks with Concurrent cisplat

Eligibility

Inclusion criteria

Inclusion criteria: 1. Biopsy proven cases of squamous cell carcinoma of oropharynx with no prior cancer directed treatment. 2. Tumor staged as III/IV as per the AJCC staging system. 3. Patient with a Karnofsky performance score (10) of 70 and above. 4. Patient who sign the informed consent and are ready to be on follow up as required.

Exclusion criteria

Exclusion criteria: 1. Age 70 years 2. Pregnant women 3. Prior invasive malignancy. 4. Patients with simultaneous primaries or bilateral tumors are excluded 5. N3 nodal status. 6. Uncontrolled co morbid conditions.

Design outcomes

Primary

Measure	Time frame
locoregional control, disease free survival,Timepoint: 6 MONTHS	—

Secondary

Measure	Time frame
acute and late toxicity, Quality of lifeTimepoint: 6 MONTHS	—

Countries

India

Contacts

Public ContactDr ANUPAM RISHI

PGIMER

anupamrishi@rediffmail.com9855900732

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026